Found: 69
Select item for more details and to access through your institution.
Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.
- Published in:
- Movement Disorders, 2015, v. 30, n. 2, p. 150, doi. 10.1002/mds.26099
- By:
- Publication type:
- Article
Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.
- Published in:
- Movement Disorders, 2013, v. 28, n. 12, p. 1675, doi. 10.1002/mds.25625
- By:
- Publication type:
- Article
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials.
- Published in:
- Movement Disorders, 2013, v. 28, n. 2, p. 131, doi. 10.1002/mds.25273
- By:
- Publication type:
- Article
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Increased levels of 5-HT<sub>1A</sub> receptor binding in ventral visual pathways in Parkinson's disease.
- Published in:
- Movement Disorders, 2012, v. 27, n. 6, p. 735, doi. 10.1002/mds.24964
- By:
- Publication type:
- Article
The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease.
- Published in:
- Movement Disorders, 2011, v. 26, n. 7, p. 1225, doi. 10.1002/mds.23631
- By:
- Publication type:
- Article
The α<sub>2</sub> adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
- Published in:
- Movement Disorders, 2010, v. 25, n. 13, p. 2084, doi. 10.1002/mds.23172
- By:
- Publication type:
- Article
Increased 5-HT<sub>2A</sub> receptors in the temporal cortex of parkinsonian patients with visual hallucinations.
- Published in:
- Movement Disorders, 2010, v. 25, n. 10, p. 1399, doi. 10.1002/mds.23083
- By:
- Publication type:
- Article
Effect of histamine H<sub>2</sub> receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
- Published in:
- Movement Disorders, 2010, v. 25, n. 10, p. 1379, doi. 10.1002/mds.23069
- By:
- Publication type:
- Article
Serotonin and Parkinson's disease: On movement, mood, and madness.
- Published in:
- Movement Disorders, 2009, v. 24, n. 9, p. 1255, doi. 10.1002/mds.22473
- By:
- Publication type:
- Article
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
- Published in:
- Movement Disorders, 2008, v. 23, n. 13, p. 1922, doi. 10.1002/mds.22086
- By:
- Publication type:
- Article
Levodopa-induced dyskinesias.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Antiparkinsonian effects of the novel D<sub>3</sub>/D<sub>2</sub> dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D<sub>2</sub>, not D<sub>3</sub>, dopamine receptors.
- Published in:
- Movement Disorders, 2006, v. 21, n. 12, p. 2090, doi. 10.1002/mds.21106
- By:
- Publication type:
- Article
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
- Published in:
- Movement Disorders, 2006, v. 21, n. 11, p. 1879, doi. 10.1002/mds.21073
- By:
- Publication type:
- Article
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure.
- Published in:
- Movement Disorders, 2006, v. 21, n. 10, p. 1578, doi. 10.1002/mds.20936
- By:
- Publication type:
- Article
Histamine H3 receptor agonists reduce.
- Published in:
- Movement Disorders, 2006, v. 21, n. 6, p. 839, doi. 10.1002/mds.20828
- By:
- Publication type:
- Article
Nondopaminergic mechanisms in levodopa-induced dyskinesia.
- Published in:
- Movement Disorders, 2005, v. 20, n. 8, p. 919, doi. 10.1002/mds.20612
- By:
- Publication type:
- Article
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
- Published in:
- Movement Disorders, 2003, v. 18, n. 11, p. 1301, doi. 10.1002/mds.10542
- By:
- Publication type:
- Article
Fipamezole (JP-1730) is a potent α<sub>2</sub> adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
- Published in:
- Movement Disorders, 2003, v. 18, n. 8, p. 872, doi. 10.1002/mds.10464
- By:
- Publication type:
- Article
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
- Published in:
- Movement Disorders, 2003, v. 18, n. 2, p. 138, doi. 10.1002/mds.10312
- By:
- Publication type:
- Article
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha<sub>2</sub> adrenoceptor antagonist idazoxan.
- Published in:
- Movement Disorders, 2001, v. 16, n. 4, p. 642, doi. 10.1002/mds.1148
- By:
- Publication type:
- Article
5-HT<sub>2C</sub> receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease.
- Published in:
- Movement Disorders, 2000, v. 15, n. 6, p. 1064, doi. 10.1002/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C
- By:
- Publication type:
- Article
The α<sub>2</sub>-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
- Published in:
- Movement Disorders, 1999, v. 14, n. 5, p. 744, doi. 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7
- By:
- Publication type:
- Article
Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.
- Published in:
- Movement Disorders, 1998, v. 13, n. 6, p. 871, doi. 10.1002/mds.870130603
- By:
- Publication type:
- Article
[<sup>3</sup>H]-2-Deoxyglucose uptake study in mutant dystonic hamsters: Abnormalities in discrete brain regions of the motor system.
- Published in:
- Movement Disorders, 1998, v. 13, n. 4, p. 718, doi. 10.1002/mds.870130419
- By:
- Publication type:
- Article
Exosome markers of LRRK2 kinase inhibition.
- Published in:
- NPJ Parkinson's Disease, 2020, v. 6, n. 1, p. 1, doi. 10.1038/s41531-020-00138-7
- By:
- Publication type:
- Article
The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 4, p. 841, doi. 10.3390/cells9040841
- By:
- Publication type:
- Article
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time.
- Published in:
- Journal of Neuroscience, 2011, v. 31, n. 19, p. 7190, doi. 10.1523/JNEUROSCI.1171-11.2011
- By:
- Publication type:
- Article
A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.
- Published in:
- FASEB Journal, 2012, v. 26, n. 5, p. 2154, doi. 10.1096/fj.11-195016
- By:
- Publication type:
- Article
Striatal histone modifications in models of levodopa-induced dyskinesia.
- Published in:
- Journal of Neurochemistry, 2008, v. 106, n. 1, p. 486, doi. 10.1111/j.1471-4159.2008.05417.x
- By:
- Publication type:
- Article
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-42847-x
- By:
- Publication type:
- Article
Selective preservation of MeCP2 in catecholaminergic cells is sufficient to improve the behavioral phenotype of male and female Mecp2-deficient mice.
- Published in:
- Human Molecular Genetics, 2013, v. 22, n. 2, p. 358, doi. 10.1093/hmg/dds433
- By:
- Publication type:
- Article
Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice.
- Published in:
- Human Molecular Genetics, 2008, v. 17, n. 10, p. 1386, doi. 10.1093/hmg/ddn026
- By:
- Publication type:
- Article
Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2.
- Published in:
- Synapse, 1996, v. 22, n. 4, p. 382, doi. 10.1002/(SICI)1098-2396(199604)22:4<382::AID-SYN9>3.0.CO;2-7
- By:
- Publication type:
- Article
Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?".
- Published in:
- 2017
- By:
- Publication type:
- letter
Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein.
- Published in:
- Acta Neuropathologica Communications, 2020, v. 8, n. 1, p. 1, doi. 10.1186/s40478-020-0894-0
- By:
- Publication type:
- Article
MOLECULAR NEURODEGENERATION.
- Published in:
- Molecular Neurodegeneration, 2010, v. 5, p. 43, doi. 10.1186/1750-1326-5-43
- By:
- Publication type:
- Article
Alternating Hemiplegia of Childhood-Related Neural and Behavioural Phenotypes in Na<sup>+</sup>,K<sup>+</sup>-ATPase α3 Missense Mutant Mice.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0060141
- By:
- Publication type:
- Article
The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset.
- Published in:
- PLoS ONE, 2012, v. 7, n. 9, p. 1, doi. 10.1371/journal.pone.0045587
- By:
- Publication type:
- Article
Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein.
- Published in:
- PLoS ONE, 2011, v. 6, n. 3, p. 1, doi. 10.1371/journal.pone.0017698
- By:
- Publication type:
- Article
Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices.
- Published in:
- British Journal of Pharmacology, 1997, v. 120, n. 8, p. 1397, doi. 10.1038/sj.bjp.0701101
- By:
- Publication type:
- Article
Monoamine Reuptake Inhibitors in Parkinson’s Disease.
- Published in:
- Parkinson's Disease (20420080), 2015, v. 2015, p. 1, doi. 10.1155/2015/609428
- By:
- Publication type:
- Article
Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold?
- Published in:
- European Journal of Neuroscience, 2019, v. 49, n. 3, p. 399, doi. 10.1111/ejn.14173
- By:
- Publication type:
- Article
Use of catechol- O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.
- Published in:
- European Journal of Neuroscience, 2013, v. 37, n. 5, p. 831, doi. 10.1111/ejn.12093
- By:
- Publication type:
- Article
Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat.
- Published in:
- European Journal of Neuroscience, 2013, v. 37, n. 2, p. 231, doi. 10.1111/ejn.12040
- By:
- Publication type:
- Article